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Objectives This study sought to determine whether variations in NOS1AP affect drug-induced long QT syndrome (LQTS).
Background Use of antiarrhythmic drugs is limited by the high incidence of serious adverse events including QT prolongation
and torsades de pointes. NOS1AP gene variants play a role in modulating QT intervals in healthy subjects and
severity of presentation in LQTS.
Methods This study carried out an association study using 167 single nucleotide polymorphisms (SNP) spanning the
NOS1AP gene in 58 Caucasian patients experiencing drug-induced LQTS (dLQTS) and 87 Caucasian controls
from the DARE (Drug-Induced Arrhythmia Risk Evaluation) study.
Results The rs10800397 SNP was significantly associated with dLQTS (odds ratio [OR]: 3.3, 99.95% confidence interval
[CI]: 1.0 to 10.8, p  3.7  10–4). The associations were more pronounced in the subgroup of amiodarone us-
ers, in which 3 SNPs, including rs10800397, were significantly associated (most significant SNP: rs10919035:
OR: 5.5, 99.95% CI: 1.1 to 27.9, p  3.0  10–4). We genotyped rs10919035 in an independent replication co-
hort of 28 amiodarone dLQTS cases versus 173 control subjects (meta-analysis of both studies: OR: 2.81,
99.95% CI: 1.62 to 4.89, p  2.4  10–4). Analysis of corrected QT interval among 74 control subjects from
our dataset showed a similar pattern of significance over the gene region as the case-control analysis. This
pattern was confirmed in 1,480 control subjects from the BRIGHT (British Genetics of Hypertension Study)
cohort (top SNP from DARE: rs12734991 in meta-analysis: increase in corrected QT interval per C allele:
9.1  3.2 ms, p  1.7  10–4).
Conclusions These results provide the first demonstration that common variations in the NOS1AP gene are associated with a sig-
nificant increase in the risk of dLQTS. This study suggests that common variations in the NOS1AP gene may have
relevance for future pharmacogenomic applications in clinical practice permitting safer prescription of drugs for vul-
nerable patients. (J Am Coll Cardiol 2012;60:841–50) © 2012 by the American College of Cardiology Foundation
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most commonly used antiar-
rhythmic drug, followed closely
by sotalol. However, use of anti-
arrhythmic drugs is limited by
the high incidence of bradycardia
and QT prolongation, which can
result in torsades de pointes
(TdP) (1–3). Amiodarone is a
class III antiarrhythmic agent in-
hibiting IKr (4,5) and increasing
action potential duration and the
effective refractory period (6,7)
(seen as QT prolongation on the
surface electrocardiogram [ECG]).
Amiodarone also decreases con-
duction velocity by blocking Na
channels (class I effect), reduces
the number of beta-adrenergic
receptors with a resultant antiad-
renergic effect (class II effect),
and suppresses Ca2-mediated
action potentials by blocking L-type calcium channels (class
IV effect). Sotalol meanwhile is an antiarrhythmic drug with
class II and class III properties (5).
It has been suggested that every individual has a physio-
logical “cardiac repolarization reserve” (8), which may be
genetically determined and which compensates for any
endogenous or exogenous factors (e.g., drugs) that would
either decrease repolarizing or increase depolarizing currents
during the action potential. It is likely, therefore, that
individuals with reduced repolarization reserve are more
vulnerable to developing QT-interval prolongation and TdP
when exposed to potassium channel–blocking drugs such as
amiodarone and sotalol.
Genome-wide analysis has consistently associated com-
mon variants of the nitric oxide synthase 1 adaptor protein
(NOS1AP) gene with QT interval across independent rep-
lication studies (9–12). Despite attempts to identify and
validate a single functional variant in NOS1AP associated
with QT interval, resequencing of all exons in NOS1AP has
not yet identified any missense mutations that explain these
results, suggesting that the functional variants associated
with these single nucleotide polymorphisms (SNP) are
likely to be regulatory in nature (9).
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Abbreviations
and Acronyms
CEU  western and
northern European ancestry
CI  confidence interval
DNA  deoxyribonucleic
acid
ECG  electrocardiogram
IRB  Institutional Review
Board
LD  linkage disequilibrium
LQTS  long QT syndrome
nNOS  neuronal nitric
oxide synthase
NOS1AP  nitric oxide
synthase 1 adaptor protein
OR  odds ratio
SNP  single nucleotide
polymorphism
TdP  torsades de pointesManuscript received November 9, 2011; revised manuscript received February 24,
2012, accepted March 6, 2012.NOS1AP is a regulator of neuronal nitric oxide synthase
(nNOS encoded by NOS1), an isoform of NOS, which
regulates intracellular calcium levels and myocyte contrac-
tion in the heart (13–15). The NOS1AP interacts with
nNOS to accelerate cardiac repolarization by inhibition of
L-type calcium channels (16–19), thereby providing a
rationale for the association of NOS1AP gene variants with
QT-interval duration.
The variability of drug action in individuals can arise
because of variation in genes encoding drug targets, genes
modulating the overall activity of the complex biological
systems within which the drugs act, and genes that are
responsible for drug metabolism and elimination. In view of
the role of NOS1AP in cardiac repolarization, we hypoth-
esized that genetic variation in the NOS1AP gene influences
the incidence of drug-induced ventricular arrhythmia and
QT prolongation.
Methods
The DARE (Drug-Induced Arrhythmia Risk Evaluation)
study is a national cohort of 112 patients experiencing
drug-induced ventricular arrhythmias and/or severe QT-
interval prolongation in the United Kingdom. A case-
control study was established from the DARE study con-
sisting of 59 Caucasian case subjects who had experienced
an arrhythmic event associated with drug-induced QT
prolongation, and 91 control subjects, all of whom had
provided deoxyribonucleic acid (DNA) samples. Ethnicity
was self-reported as Caucasian for all cases and controls.
Cases were included if they had 1 or more of the
following diagnosed as secondary to a medication: docu-
mented classical TdP defined as 3 beats or more of poly-
morphic ventricular tachycardia associated with QT prolon-
gation and pauses prior to onset of the arrhythmic event;
ventricular fibrillation and/or cardiac arrest associated with
corrected (QTc)-interval prolongation; and QTc-interval
prolongation with a history consistent with cardiac syncope,
excluding vasovagal syncope and seizures. After withdrawal
of the culpable drug, cessation of ventricular arrhythmia and
syncope and at least partial resolution of QT prolongation
were required. All QTc intervals were corrected using
Bazett’s formula and values 450 ms (men) or 470 ms
(women) were considered prolonged. Cases were excluded if
DNA was unavailable and/or arrhythmias were not docu-
mented and/or QT prolongation was absent.
Healthy control subjects were provided from primary care
physicians responsible for the cases to ensure geographical
matching. Inclusion criteria were no history of drug-
induced arrhythmias, ventricular arrhythmias, or the con-
genital long QT syndrome (LQTS). Control subjects with
abnormal resting 12-lead ECGs were excluded.
Clinical and ECG assessment. The case subjects’ acute
presentation with arrhythmia and/or syncope and past
medical history were assessed by obtaining hospital records,
interview, and patient questionnaires. The QT and RR
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August 28, 2012:841–50 NOS1AP and Drug-Induced QT Prolongationintervals were measured manually from paper ECGs at
stable heart rates by averaging them for up to 5 cardiac
cycles (up to 10 cardiac cycles in atrial fibrillation) and
Bazett’s formula was used to calculate the heart rate cor-
rected QTc interval.
Case subjects, with drug exposure removed, and control
subjects underwent resting 500-Hz digital 12-lead ECGs
acquired using PC-based Cardionavigator recorders (Del
Mar Reynolds, Spacelabs Healthcare, Issaquah, Washing-
ton). Each automatically calculated QT interval was
checked manually. If they were similar, the automatic
measurement was not revised. If not, then the same method
described for manual measurements was used.
NOS1AP sequencing. Gene sequencing of NOS1AP
ENSG00000198929) exons and intron/exon boundaries
as carried out for all case subjects and control subjects
sing the ABI3130 System (Applied Biosystems, The
edical Biomics Centre, St. George’s University London
SGUL], London, United Kingdom) (primers available on
equest).
OS1AP Association Study
ne hundred and ninety-eight tagging SNPs, derived from
he National Center for Biotechnology Information’s build
5 of the NOS1AP gene, were genotyped in all case subjects
nd control subjects using the Infinium Human_CVD 50K
ead Array (Illumina-IBC/CVD, Illumina Inc., San Diego,
alifornia) (20) and were analyzed using the Illumina
latform 500GX (Medical Biomics Centre, SGUL). Seven
NP covered up to 4.3 kb of the upstream region of
OS1AP from the start site of the gene, and after rese-
uencing, we found 2 more SNP, which we added to the
ataset. The downstream region of the gene was not
overed. Two outliers (1 case subject and 1 control subject)
ere excluded from the analysis as they had 10% missing
ata. We checked for ethnic outliers using the complete
enetic dataset of the CVD chip. Multidimensional scaling
nalysis in PLINK (version 1.07, Shaun Purcell, Center for
uman Genetic Research, Boston, Massachusetts) (21,22)
evealed that 3 control subjects were not of Caucasian
escent despite their self-reported Caucasian ethnicity.
fter these exclusions, there were 58 cases and 87 controls
vailable for analysis. The average call rate of the remaining
ubjects was 99.9%. Thirty-three SNPs were nonpolymor-
hic, hence 167 SNPs could be analyzed for association with
T-interval prolongation and drug-induced ventricular
rrhythmia.
OS1AP rs10919035 replication cohort. CASES. For vali-
dation, an independent set of 28 amiodarone-treated pa-
tients collected at Vanderbilt University Medical Center,
under appropriate Institutional Review Board (IRB)-
approved protocols was used. Patients were of European
descent from North America with drug-induced LQTS,
defined as documented TdP associated with reversible QT
prolongation during treatment with amiodarone. Covariates dincluded age, sex, self-reported ethnicity, hypokalemia, and
the culprit drug at the time of the index arrhythmia.
REPLICATION DRUG-EXPOSED CONTROLS. One hundred and
five self-identified European ancestry subjects derived from
a clinical study at Vanderbilt University Medical Center,
under an IRB-approved protocol were included as drug-
exposed control subjects. The study uses electronic medical
record–based surveillance to identify patients in whom
assorted QT prolonging antiarrhythmics were being
initiated.
REPLICATION NORMAL CONTROLS. Sixty-eight self-identified
European ancestry subjects derived from a clinical study at
Vanderbilt University Medical Center, under an IRB-
approved protocol were included as drug-exposed control
subjects. Control subjects were normal, healthy volunteers
recruited from the general population and challenged with
an antiarrhythmic drug (ibutilide) (23).
For this study, control subjects were defined as having the
absence of qualifying arrhythmias, 50 ms increase in QTc
(by Bazett’s formula) interval on drug exposure, and no QTc
interval exceeding 500 ms during drug treatment or ibutilide
challenge.
The frequency distributions of the 2 control samples were
similar, and hence the control data were pooled for analysis.
QTc replication cohort. BRIGHT. Over 2,000 unrelated
white European hypertensive individuals from the BRIGHT
(British Genetics of Hypertension Study) study (24) were
genotyped using the Human_CVD BeadChip (Illumina).
Of those, 1,909 individuals passed quality control checks
(samples with low call rate, cryptic duplicates and relatives,
outliers in ancestry principle component analysis, sex X
chromosome mismatch were excluded). Of the 1,909, 1,628
individuals had 12-lead ECG recordings (Siemens-
Sicard440, Siemens, Berlin, Germany) (25). For this anal-
ysis, we excluded individuals with QRS duration 120 ms
(n 83), and individuals with atrial fibrillation or persistent
utter (Minnesota codes 8-3-1 or 8-3-2; n  25). No data
ere available for antiarrhythmic drug consumption. We
lso excluded individuals with a missing covariate (age; n 
0). Thus, data on 1,480 individuals were tested for asso-
iation. We used a normal linear model with QTc as
utcome and sex, age, and 10 ancestry principal components
s covariates to control for population stratification. We
nalyzed all SNPs within 50 kb of the NOS1AP transcript,
pecifically from rs4657139 (chr1:160296531) to rs457879
chr1:160602678) inclusive. We excluded SNPs that could
ot be called with high confidence (4 SNPs) and 1 SNP
ith a call rate below 98%. The results for 195 SNPs were
rovided.
tatistical analysis. Case subjects and control subjects from
he DARE study were compared for population characteristics
sing a chi-square test (sex) and Mann-Whitney U test (age
nd QTc interval). Genotype frequencies were tested for
ardy-Weinberg equilibrium using the chi-square test with 1egree of freedom. The genotype frequencies, assuming an
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case subjects and control subjects, between subjects on amio-
darone and control subjects, and between subjects on sotalol
and control subjects (case-control analysis) using logistic re-
gression analysis in PLINK (version 1.07) (21,22). Age and sex
were not used as covariates because the sex distribution
appeared not to be significantly different between case subjects
and control subjects, and control subjects appeared to be older
than case subjects were; hence, they were more likely to develop
QT prolongation or ventricular arrhythmia but, nevertheless,
did not demonstrate either. As QTc interval appeared to be
significantly longer among the case subjects after removal of
the drug than among the control subjects, we also tested the
model where QTc interval was included to correct for possible
mediating effects. Case subjects who had a ventricular- or
atrioventricular-paced ECG or a left branch bundle block were
excluded from this analysis (n  12). The same analysis was
performed in the replication study for our top SNP
rs10919035.
In addition, we studied QTc interval as a quantitative
trait in the population-based DARE control sample (74 of
87 controls had data on QTc interval available) in order to
Characteristics of Case Subjects and Control Subjects Included inTable 1 Characteristics of Case Subjects and Control Subjects
DARE Case
Subjects
DARE Control
Subjects
n 58 87
Age, yrs 62.5 15.5 71.1 10.5*
Female 39 (67) 46 (56)
Culpable drug exposure†
Amiodarone 27 (47) —
Sotalol 15 (26) —
Diuretics 6 (11) —
1 drug 16 (28) —
Presentation
Documented torsades de pointes 50 (89) —
Ventricular fibrillation/cardiac arrest 12 (21) —
Syncope only 2 (4) —
Hypokalemia 11 (20) —
Other medical history
Prior myocardial infarction 14 (25) —
Heart failure‡ 12 (21) 0 (0)
Atrial fibrillation and/or flutter 29 (52) —
Congenital long QT syndrome* 2 (4) 0 (0)
Hypertension 32 (57) —
Hypothyroidism 11 (20) —
Diabetes mellitus 14 (25) —
Maximal QTc during drug exposure, ms
Mean  SD 592 73.3
Range 466–850 —
Median 590
QTc without drug exposures, ms‡
Mean  SD 441 25.9 426 18.2*
Range 381–503 379–469
Median 435 423
Values are mean  SD or n (%) unless otherwise indicated. Dashes indicate that data are not ava
ubjects and 74 control subjects.
BRIGHT  British Genetics of Hypertension Study; DARE  Drug-Induced Arrhythmia Risk Evaluation; Nreplicate published associations. Case subjects were not
included in this analysis as they had a longer QTc interval
even after removal of the drug and hence were not repre-
sentative of the population. A linear regression was per-
formed for each SNP following an additive model on QTc
interval with SNP, age, and sex as covariates. A similar
analysis was done in the BRIGHT cohort (n  1,480) and
he results of the 2 cohorts were meta-analyzed using the
xed-effect inverse variance method in PLINK (version
.07) (21,22).
Because multiple SNP were tested, a multiple testing
orrection was applied using SNP Spectral Decomposition
26,27). This method calculates the effective number of
ndependent marker loci accounting for linkage disequilib-
ium between the SNP. With this number, a Bonferroni
orrection is applied to assess the significance threshold. For
ur dataset of 167 SNP in the NOS1AP gene, the effective
number was 98.8, and hence a p value less than 0.00052 was
considered statistically significant. Odds ratios (OR) and
99.95% confidence intervals (CI) were calculated to assess
the strength of the association. Because only 1 SNP was
genotyped in the replication study for amiodarone-induced
nalysesded in the Analyses
anderbilt Case
Subjects
Vanderbilt Healthy
Control Subjects
Vanderbilt
Control Subjects BRIGHT
28 68 105 1,480
64 15.16 26.8 5.61 62.2 14.26 57.7 10.18
21 (75) 37 (53) 38 (36) 916 (61.9)
28 (100) — — —
— — — —
9 (32) 0 43 (41)
0 0 0
28 (100) NA 0
0 NA 0
0 NA 0
7 (25) NA 0
3 (10) NA 14 (14) 0 (0)
9 (32) NA 1 (.009) 0 (0)
18 (64) NA 97 (92) 0 (0)
0 NA 0 0 (0)
13 (46) NA 65 (62) 1,480 (100)
0 NA 18 (17) 0 (0)
0 NA 20 (19) 0 (0)
434 467 —
584 375–492 403–556
523–840 428 464
613
430 388 443 417 12.0
344–505 367–457 367–565 343–704
428 406 442 420
p0.05. †Available for 57 case subjects. ‡From questionnaire data only. §Available for 44 casethe AInclu
V
ilable. *A  not applicable; QTc  corrected QT interval.
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August 28, 2012:841–50 NOS1AP and Drug-Induced QT ProlongationQTc interval, a p value 0.05 was considered significant in
his cohort.
esults
tudy characteristics. Fifty-eight subjects experiencing
drug-induced QT prolongation and ventricular arrhythmias
(50 [89%] with documented TdP), and 87 healthy control
subjects from the DARE study (Table 1) were available for
the primary analysis. Control subjects were on average
almost 9 years older than case subjects were (p 0.001). No
sex difference was observed. Twenty-seven (46%) cases were
treated with amiodarone and 15 (27%) with sotalol, whereas
15 (27%) had received more than 1 culpable drug. Eleven
cases (20%) were associated with hypokalemia. The cases
also had a higher frequency of accompanying structural
heart disease and, when the drug exposure was removed,
demonstrated greater QTc prolongation than the control
subjects did (p  1.0  10–3).
DNA sequencing and association analysis. Sequencing of
the NOS1AP exonic regions and intron/exon boundaries on
hromosome 1 did not identify any novel coding mutations
Figure 1 Regional Association Plot for NOS1AP SNPs
Statistical significance of single nucleotide polymorphisms (SNPs) are shown on th
monds), and the sotalol users (green triangles). The recombination rate is shown
SNPs (p  0.01) are shown in the top of the figure (whole group in red; amiodaro
diamond. The correlation of this SNP to other SNPs at the NOS1AP locus is shown
SNPs previously associated with corrected QT-interval prolongation in the general
the lower part of the figure. Figure made using an adapted version of the R script
SNPs using HapMap. Bioinformatics 2008;24:2938–9).r polymorphisms. However, resequencing 2 kb upstream of
he ATG site identified 2 additional SNP that were not
ncluded on the Human_CVD 50K Bead Array and these
ere included in the association analysis.
SNP rs10800397 was significantly associated with drug-
nduced ventricular arrhythmia and QT prolongation (OR:
.3, 99.95% CI: 1.0 to 10.8, p  3.7  10–4) (Fig. 1,
able 2). This association was driven by the group of
miodarone users (rs10800397: OR: 4.5, 99.95% CI: 1.0 to
9.8, p 4.3 10–4; case subjects: 37.0%, control subjects:
14.4%) (Fig. 1, Table 2). For this subgroup of cases, 3
noncoding SNPs were significantly associated with drug-
induced ventricular arrhythmia and QT-interval prolonga-
tion (most significant SNP rs10919035: OR: 5.5, 99.95%
CI: 1.1 to 27.9, p  3.0  104; allele frequencies: case
ubjects: 27.8%, control subjects: 7.1%). These SNPs did
ot include either of the SNP rs10494366 (OR: 1.1, p 
.79; allele frequencies amiodarone-induced: case subjects:
7.0%, control subjects: 35.1%) and rs16857031 (OR: 1.8,
 0.13; allele frequencies amiodarone-induced: case
ubjects: 27.8%, control subjects: 19.0%) known to be
(p) scale for the whole group (red squares), the amiodarone-users (blue dia-
right axis. Odds ratios (OR) and 99.95% confidence intervals (CI) of the top
rs in blue). The most significantly associated SNP is represented by a large blue
scale from minimal (white) to maximal (bright red/green/blue). The rs-ids of
tion or that where in strong linkage disequilibrium with such SNPs are given in
P (Johnson AD. SNAP: a web-based tool for identification and annotation of proxye –log
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NOS1AP and Drug-Induced QT Prolongation August 28, 2012:841–50associated with variation in resting QTc nor SNPs that were
in strong linkage disequilibrium with them (9,11,12). The
remaining NOS1AP SNPs previously associated with resting
QTc (rs12143842, rs12029454, rs4657178) were not in-
cluded on the array and hence could not be investigated
directly. However, SNPs that were in strong linkage dis-
equilibrium (LD) with these in the HapMap (Haplotype
Map) Project’s western and northern European ancestry
(CEU) population (26) and that were present on the chip
were not associated with amiodarone-induced ventricular
arrhythmia and QT interval prolongation, except for SNP
rs6427664, which was in LD with rs4657178 (r2  0.82 in
HapMap CEU sample) and showed suggestive association
(OR: 3.4, 99.95% CI: 0.8 to 14.0, p  0.0025). Including
QTc interval as a covariate in the model weakened the
associations, but the ORs did not change (Table 3). None of
the SNP was statistically significantly associated with
sotalol-induced ventricular arrhythmia and QT-interval
prolongation, although the top SNPs were the same as for
amiodarone (Tables 2 and 3).
The most significant SNP (rs10919035) was also geno-
typed in the replication cohort of 28 cases with amiodarone-
induced LQTS and 173 drug-challenged control subjects.
The effect of this SNP showed a trend in the same direction
as that observed in the DARE cohort (allele T: 26.8%
among case subjects versus 16.5% in drug-challenged con-
trol subjects; p  0.060). Meta-analysis of the results of
rs10919035 from both studies revealed an OR of 2.81 for
each T allele (99.95%: CI 1.62 to 4.89, p  2.4  10–4).
To validate the reported association between NOS1AP
nd QTc interval duration, the 167 SNP spanning the
OS1AP gene were examined for association in the
opulation-based DARE control subjects (n 74). None of
he SNPs was significantly associated with QT interval after
ultiple testing correction (Table 4, Fig. 2A). To extend
his analysis, we combined the data in a meta-analysis with
hose of the BRIGHT cohort (n  1,480) (Table 4,
Fig. 2A). The results of the BRIGHT cohort were similar
to those of the DARE cohort and, although the associations
were more significant, the effect sizes were 2 to 4
smaller. SNP rs12734991 showed the largest increase in
QTc interval in the DARE cohort (  11.1 ms per C
allele, p  6.4  10–4), and it was second in the meta-
nalysis (  4.2 ms per C allele, p  3.5  10–6). The
most associated SNPs overlap with those SNPs arising from
the case-control analysis. SNP rs10800397, which showed
the strongest association with drug-induced ventricular
arrhythmia and QT-interval prolongation, also caused an
increase in QTc interval in the control subjects (in DARE/
meta-analysis:   11.5/4.6 ms per T allele, p  0.019/4.3 
0–5). In addition, SNP rs6427664, which was in LD with
s4657178, reached a significance level of 0.012/9.1  10–5 in
DARE/meta-analysis (  11.1/4.2 ms per A allele). In
contrast, SNP rs10494366 and rs16857031 were not signif-
icant (p  0.85/0.005 and 0.95/22, respectively, in DARE/To
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August 28, 2012:841–50 NOS1AP and Drug-Induced QT Prolongationmeta-analysis), and neither were SNPs that were in strong
LD with other previously QTc-associated nontyped SNPs
rs12143842 and rs12029454.
Discussion
This study is the first to demonstrate that common
variations in the NOS1AP gene are associated with a
significant increase in the risk of drug-induced, and in
particular amiodarone-induced, ventricular arrhythmia
and QT prolongation. Prolongation of the QT interval
associated with TdP is currently the most common cause
of withdrawal or restriction of the use of antiarrhythmic
drugs (29).
We performed a comprehensive screen of 167 SNPs in
and close to the NOS1AP gene in order to investigate
association of NOS1AP variations with drug-induced ven-
tricular arrhythmia and prolongation of the QT interval.
SNP rs10800397 reached a significance level of p  3.7 
10–4 in the overall DARE case-control study and this was
predominantly explained by the subgroup of amiodarone
users (p  4.3  10–4). For this subgroup of cases, 3 SNPs
ere significantly associated with drug-induced ventricular
rrhythmia and QT-interval prolongation. The most signif-
cant one, rs10919035, was in moderate LD with
s10800397 (r2  0.49). We carried out a replication study
sing amiodarone-treated cases from a second study (Van-
erbilt) and these were compared with a drug-challenged
ontrol group. Although we could not fully validate our
esults from the DARE cases and nondrug-challenged
ontrol subjects, meta-analysis of the results of rs10919035
rom both studies revealed an OR of 2.81 for each T allele
99.95% CI: 1.62 to 4.89, p  2.4  10–4). Interestingly,
the allele frequency among the replication and DARE cases
Top Drug-Induced Arrhythmia Associated SNPs (p < 0.01) Correctethe Group of 13 Sotalol Users, and the Whole Group of 44 as SuTable 3 Top Drug-Induced Arrhy mia Associated SNPs (p < 0.the Group of 13 Sotalol Users, and the Whole Group o
Amiodarone Users
SNP Minor Allele p Value OR 99.95% CI
rs10919035 T 0.0023 6.6 0.8–56.7
rs10800397 T 0.066 2.8 0.4–20.7
rs10800404 T 0.066 2.8 0.4–20.7
rs10800352 G 0.0098 4.5 0.6–34.8
rs7522678 A 0.016 4.0 0.5–29.5
rs10800409 T 0.013 4.0 0.6–27.1
rs6427664 A 0.21 1.9 0.3–12.0
rs10918859 A 0.036 3.3 0.5–23.6
rs12403202 T 0.044 2.5 0.5–12.5
rs12742393 A 0.74 1.2 0.3–5.3
rs6664702 C 0.078 2.6 0.4–16.2
rs10753784 G 0.31 1.6 0.3–7.2
rs4298709 G 0.55 1.3 0.3–6.8
rs4531275 T 0.089 2.3 0.4–11.9
rs10399680 C 0.47 1.4 0.3–7.1
SNPs are sorted in the same order as in Table 2. Significant SNPs (p  5.2  10–4) are denoted
Abbreviations as in Tables 1 and 2.was identical. The nonsignificance in the replication study mappears to be caused by the unexpectedly higher frequency
among the control subjects (17% versus 7% in DARE
control subjects, 8% in 1000Genomes CEU, and 11% in
HapMap Phase 2 CEU (28)) and might therefore be a
population-specific effect. It is also important to note that
some of the drug-challenged control subjects were chal-
lenged with ibutilide. Unlike amiodarone, ibutilide does not
produce its prolongation of action potential via inhibition of
potassium channels including IKr, nor does it have a
sodium-blocking, antiadrenergic, and calcium-blocking ac-
tivity.
In contrast, ventricular arrhythmia and QT prolongation
induced by sotalol were not significantly affected by
NOS1AP, although the same SNPs demonstrated the larg-
est genotype differences with smaller ORs. This subgroup
was too small (n  15) to draw any certain conclusions
about drug-specific interactions.
A common pathway between amiodarone-induced
LQTS and NOS1AP common variation could be the role of
he NOS regulator pathway in cardiac L-type CaV currents.
n the prospective population-based Rotterdam Study, van
oord et al. (28) associated minor alleles of the NOS1AP
SNP rs10494366 and rs10918594 with the modification of
the QTc prolonging effect of verapamil. Furthermore,
Chang et al. (16) found that overexpression of the NOS1AP
gene product in isolated guinea pig myocytes causes atten-
uation of the L-type CaV current, a slight increase in rapid
delayed rectifier current (IKr), and shortening of action
potentials.
Data from the congenital LQTS may also support such a
mechanism. Rare variants in the LQT8 gene CACNA1C,
encoding a subunit of the L-type CaV channel, cause an
nusual form of LQTS by increasing calcium influx into the
QTc Interval in the Group of 19 Amiodarone Users,s Compared With 74 Control Subjectsorrected for QTc Interval in the Group of 19 Amiodarone Users,
ase Subjects Compared With 74 Control Subjects
Sotalol Users All Cases
Value OR 99.95% CI p Value OR 99.95% CI
.14 2.9 0.2–37.2 0.011 3.5 0.6–19.3
.13 2.7 0.3–27.6 0.014 2.8 0.7–11.9
.13 2.7 0.3–27.6 0.024 2.6 0.6–10.9
.035 3.7 0.4–31.8 0.014 2.7 0.7–10.7
.21 2.3 0.2–23.2 0.069 2.2 0.5–9.3
.10 2.8 0.3–23.7 0.027 2.7 0.6–12.3
.51 1.5 0.2–10.7 0.22 1.6 0.4–5.6
.046 3.4 0.4–28.3 0.028 2.4 0.6–10.0
.51 0.7 0.1–5.9 0.37 1.4 0.4–4.4
.33 1.6 0.3–8.7 0.23 1.5 0.5–4.5
.18 2.2 0.3–16.3 0.12 1.8 0.5–6.8
.82 0.9 0.2–5.2 0.42 1.3 0.4–3.8
.71 0.8 0.1–5.6 0.34 1.4 0.4–4.1
.18 2.2 0.3–15.8 0.079 1.9 0.5–6.3
.89 1.1 0.2–6.9 0.56 1.2 0.4–4.1
Other p values 0.01 are shown in italic.d forbject01) C
f 44 C
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NOS1AP and Drug-Induced QT Prolongation August 28, 2012:841–50alpha-1-syntrophin (SNTA1), has also been shown to be
involved in the nNOS pathway (19). A mutation in the
gene causes inhibition of nNOS and is associated with
increased peak and late sodium currents. Therefore,
genes encoding proteins interacting with nNOS have the
potential to alter cardiac repolarization, perhaps by in-
fluencing calcium cycling in cardiac myocytes. NOS1AP
minor allele variants have more recently been associated
with modification of the severity of presentation of
LQTS (31,32) and the risk of sudden death in coronary
artery disease (33).
In addition, we studied QT interval as a quantitative trait
in population-based control subjects. In the meta-analysis of
the DARE control subjects (n  74) and the BRIGHT
cohort (n  1,480), 22 SNPs reached significance (p 
5.2  10–4). Although the results in the BRIGHT cohort
ere more significant as a result of the larger sample size,
he effects of the SNPs were 2 to 4 smaller than in the
ARE control subjects. Furthermore, many of the top hits
f this analysis overlap with the top hits of the drug-induced
Top SNPs From the DARE Cohort (p < 0.05) Associated With theC ntinuous QTc Interval in 74 Control Subjects Ordered Accordinggether With the Results of the BRIGHT Cohort (n  1,480) a d
Table 4
Top SNPs From the DARE Cohort (p < 0.05) Associate
Continuous QTc Interval in 74 Control Subjects Ordere
Together With the Results of the BRIGHT Cohort (n 
DARE
SNP Position Allele Beta SE p Val
rs12734991 160461200 C 11.1 3.1 6.4  1
rs4657166 160427963 G 11.5 3.6 0.002
rs12733377 160519067 G 9.3 3.1 0.003
rs12729882 160508661 A 8.9 3.0 0.004
rs2661818 160531438 G 8.6 3.0 0.005
rs10399680 160480119 C 11.1 3.8 0.005
rs6664702 160471531 C 11.7 4.4 0.009
rs1964052 160602048 T 11.6 4.4 0.011
rs4298709 160503206 G 8.5 3.3 0.011
rs10918936 160469112 A 8.1 3.1 0.011
rs6427664 160481097 A 11.1 4.3 0.012
rs905720 160600724 T 8.5 3.5 0.018
rs4557949 160477578 A 8.0 3.3 0.019
rs4145621 160485312 C 8.0 3.3 0.019
rs10800397 160503714 T 11.5 4.8 0.019
rs10800404 160521736 T 11.5 4.8 0.019
rs12135795 160416389 A 7.6 3.2 0.019
rs10753765 160418397 G 7.6 3.2 0.019
rs3927640 160422437 T 7.6 3.2 0.019
rs4657161 160422913 G 7.6 3.2 0.019
rs12090585 160305400 A 8.9 3.9 0.024
rs347271 160585953 A 19.6 8.7 0.027
rs4328057 160458029 G 19.7 8.8 0.028
rs10918951 160475138 A 11.6 5.4 0.036
rs16859092 160491174 C 11.6 5.4 0.036
rs12742393 160491210 A 6.9 3.3 0.039
rs4656364 160545479 C 10.0 4.8 0.040
rs10753784 160515544 G 6.6 3.2 0.043
rs10919035 160510636 T 14.1 6.9 0.043
Significantly associated SNPs are shown in bold (p  5.2  104). p values 0.01 are shown in
SE  standard error; other abbreviations as in Tables 1 and 2.ase-control analysis. This implies that the effect of aOS1AP on drug-induced LQTS is not independent of the
ffect of NOS1AP on QT interval in general. Because case
ubjects and control subjects already demonstrated signifi-
antly different mean QTc intervals after drug removal, we
lso corrected the case-control drug-induced LQTS interval
nalysis for baseline QTc interval. Although the results
ecame less significant, the ORs only diminished slightly.
his suggests that the investigated QT-interval prolong-
ng drugs and in particular amiodarone interact with
OS1AP variants. Unfortunately, our study design does
ot allow testing for interactions directly as all case
ubjects used drugs, whereas none of the DARE control
ubjects did and the drug-challenged control subjects
rom the Vanderbilt study were not on amiodarone
pecifically. The findings do lend support, however, to
epolarization reserve being influenced by common ge-
etic variation.
Another explanation for the larger QTc interval among
ase subjects after removal of the drug may be that the case
ubjects demonstrated a higher frequency of hypertension
eir SignificanceMeta-Analysis of the 2 Cohortsith the
cording to Their Significance
0) and of the Meta-Analysis of the 2 Cohorts
BRIGHT Meta-Analysis
Beta SE p Value Beta SE p Value
3.5 0.9 1.7  10–4 4.2 0.9 3.5  10–6
2.6 1.0 0.010 3.2 1.0 0.00091
3.3 0.9 4.0  10–4 3.8 0.9 2.0  10–5
3.1 0.9 8.6  10–4 3.6 0.9 5.2  10–5
4.0 0.9 1.7  10–5 4.4 0.9 6.1  10–7
3.7 1.1 7.9  10-4 4.2 1.0 5.7  10–5
3.6 1.1 0.0013 4.1 1.1 1.6  10–4
1.1 1.4 0.44 0.1 1.3 0.95
3.0 0.9 0.0015 3.4 0.9 1.6  10–4
2.9 1.0 0.0025 3.3 0.9 2.5  10–4
3.7 1.1 7.6  10–4 4.2 1.1 9.1  10–5
0.4 1.0 0.73 0.4 1.0 0.72
3.8 0.9 4.9  10–5 4.1 0.9 4.8  10–6
3.9 0.9 3.7  10–5 4.2 0.9 3.5  10–6
4.2 1.1 3.0  10–5 4.6 1.1 4.3  10–5
4.4 1.2 1.4  10–4 4.8 1.1 1.9  10–5
2.3 0.9 0.016 2.7 0.9 0.0026
2.3 0.9 0.016 2.7 0.9 0.0026
2.3 0.9 0.015 2.7 0.9 0.0025
2.3 0.9 0.015 2.7 0.9 0.0025
NA NA NA NA NA NA
2.4 2.5 0.34 3.7 2.4 0.12
1.8 3.1 0.57 0.6 2.9 0.84
0.2 2.1 0.91 1.7 2.0 0.38
0.2 2.1 0.92 1.3 2.0 0.50
3.2 0.9 7.5  10–4 3.5 0.9 1.3  10–4
3.3 1.5 0.033 3.9 1.5 0.0076
3.3 1.0 5.5  10–4 3.6 0.9 9.4  10–5
5.1 1.4 3.3  10–4 5.5 1.4 8.1  10–5to Thof thed W
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August 28, 2012:841–50 NOS1AP and Drug-Induced QT Prolongationsubjects did. These are known acquired risk factors for
QT-interval prolongation and TdP (34).
There are currently no published functional studies in-
vestigating variable expression of NOS1AP polymorphisms.
Given the shared effects of NOS1AP and amiodarone on
L-type calcium and potassium currents, however, one might
hypothesize that individuals carrying genetic variants in
NOS1AP, which impair its expression, and in turn, result in
increased L-type calcium currents and/or QT prolongation,
may have additional arrhythmogenic risk with amiodarone
therapy. These common variants may have relevance for
future pharmacogenomic applications in clinical practice
permitting safer prescription of amiodarone for vulnerable
patients. Development of safer novel drugs may also benefit
from this improved understanding of the biological path-
ways underlying the variation in drug response.
Study strengths. First, the DARE case subjects were
collected prospectively and nationally in a systematic man-
ner with identical comprehensive phenotyping, a strength
compared with other series. Second, the coverage of the
NOS1AP gene was comprehensive and included 167 poly-
morphic SNPs in and close to the NOS1AP gene. Third,
Figure 2 Association of the NOS1AP SNPs
With the Continuous QTc Interval
(A) Association of the NOS1AP single nucleotide polymorphisms (SNP) with the
continuous corrected QT (QTc) interval in the DARE (Drug-Induced Arrhythmia
Risk Evaluation) study control subjects (white diamonds) (n  74), in the
BRIGHT cohort (gray diamonds) (n  1,480), and in the meta-analysis of the 2
cohorts (black diamonds) (n  1,554) and (B) association of the NOS1AP
SNP with the continuous QTc interval in the DARE-BRIGHT meta-analysis (black
diamonds) (n  1,554) and with dichotomous drug-induced ventricular arrhyth-
mia and QT-interval prolongation (gray squares) (n  58 case subjects and 87
control subjects).the high ORs and level of significance despite smallnumbers provides compelling support for the association
as does the similar frequency of SNPs in cases in the
replication case-control study and the trend toward a
significant association.
Study limitations. First, we were limited by the rarity of
subjects treated with amiodarone that presented with ven-
tricular arrhythmia and QT prolongation. Second, whereas
the DARE control subjects were originally matched for age,
sex, and ethnicity, it was difficult to also match for drug
exposure and other comorbidity, which results in difficulties
in determining whether the associations identified are
caused by drug exposure or by the underlying arrhythmic
event. The replication case-control study was however able
to use controls exposed to QT-prolonging drugs although
not amiodarone specifically. Third, as with previous rese-
quencing efforts of NOS1AP (9), we did not identify any
missense mutations that explain the association results. The
associated NOS1AP SNPs are therefore not functional
ariants and are only in linkage disequilibrium with the
ausal SNP or regulatory DNA element.
onclusions
ur study shows that common variants in the NOS1AP
ene play a role in the pathogenesis of drug-induced, and
articularly amiodarone-induced, LQTS. These variants
ay be used in the future as markers to predict and avoid
isk for drug-induced TdP in Caucasian patients who may
equire amiodarone therapy.
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